 |
|
| |
| |
 |
| - |
Foreword |
| - |
Advisory Board |
| - |
Introduction - CCT |
| - |
Training and Education
Provided by CCT |
| - |
SFDA Inspection and Accreditation |
| - |
Ethics Committee |
| - |
Central Laboratories |
| - |
Clinical Trials Capabilities |
|
Cardiology |
|
Clinical Oncology |
|
Digestive and
Liver Diseases |
|
Endocrinology |
| |
Ophthalmology |
| |
Phase I Studies Unit |
| |
Paediatrics |
| |
Anaesthesia and
Intensive Care |
| |
Community and
Family Medicine |
| |
Neurology |
| |
Orthopedic and
Traumatology |
| |
Psychiatry |
| |
Rheumatology |
| |
Surgery |
|
|
|
|
Clinical Trials Capabilities > Ophthalmology |
|
Strength and Expertise
- Capable of performing multicenter studies at 3 SFDA accredited centers:
- Prince of Wales Hospital;
- Hong Kong Eye Hospital; and
- Joint Shantou International Eye Centre
- Experienced optometrists, nurses and research staff
- Certified investigation modalities: ETDRS VA test, OCT, and FA.
- Basic laboratory support available: genetics and ocular pathology
Special Facility and Equipment
- Anterior segment OCT
- Fluorescein and ICG angiography
Clinical Trials Monitored and/or Audited by Industry, FDA and local RGC etc.
- Safety and efficacy of pirenzepine 2% ophthalmic gel in children with myopia
- Safety and efficacy of dexamethasone posterior segment drug delivery system (DEX PS DDS) 700 £gg and 350 £gg applicator system for macular edema following retinal vein occlusion
- Safety and efficacy of intravitreal fluocinolone acetonide implants (0.59 mg and 2 mg) for clinically significant diabetic macular edema
- Safety and efficacy of an intravitreal fluocinolone acetonide implant (0.59 mg or 2 mg) for non-infectious uveitis
|
|
|
|
|
| |
|
 |
